MedPath

Bavaria Considers Purchasing Sputnik V Vaccine Pending EMA Approval

• Bavaria has negotiated a preliminary contract to receive 2.5 million doses of the Russian Sputnik V vaccine, pending approval by the European Medicines Agency (EMA). • R-Pharm Germany, a subsidiary of Russian drugmaker R-Pharm, could potentially produce the Sputnik V vaccine in Bavaria, contingent on EMA approval. • Several EU member states have criticized the slow pace of vaccine distribution, with some, like Austria and Slovakia, also considering negotiating for the Russian vaccine.

The German state of Bavaria is considering the purchase of 2.5 million doses of the Russian Sputnik V vaccine, despite it not yet being approved by the European Medicines Agency (EMA). A "preliminary contract" has been negotiated, according to regional leader Markus Soder.
Soder stated that Bavaria would receive the doses if Sputnik V gains approval in Europe. This move comes amid criticism of the EU's vaccine distribution efforts, which some member states perceive as slow. Austria and Slovakia have also expressed interest in negotiating for the Russian vaccine.
R-Pharm Germany, a subsidiary of Russian pharmaceutical giant R-Pharm, has a production line in Illertissen, Bavaria. This facility could potentially produce the Sputnik V vaccine, pending regulatory approval. Hungary is currently the only EU member state using Sputnik V to vaccinate its citizens.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

European Commission Approves BioMarin's Roctavian for Severe Hemophilia A

The European Commission granted conditional marketing approval for BioMarin's Roctavian (valoctocogene roxaparvovec) for severe hemophilia A in adults without Factor VIII inhibitors.
Roctavian, a one-time gene therapy, delivers a functional Factor VIII gene using an adeno-associated virus vector, potentially offering a curative treatment option.

EMA Official Urges Caution on National Approvals for Sputnik V Vaccine

A senior EMA official advises EU members against granting national approvals for Russia's Sputnik V COVID-19 vaccine during the agency's ongoing review.
The EMA cites a lack of data on vaccinated individuals and the need for thorough evaluation according to European standards.

Germany Considers Purchasing Sputnik V Vaccine Pending EMA Approval

German Chancellor Angela Merkel stated Germany would consider purchasing the Sputnik V vaccine if it receives approval from the European Medicines Agency (EMA).
The EMA currently lacks sufficient information regarding the Sputnik V coronavirus vaccine, causing a delay in potential approval.

EMA Postpones Decision on Sputnik V Vaccine Approval Until September

The European Medicines Agency (EMA) has delayed its decision on approving the Russian Sputnik V vaccine, with a decision expected no earlier than September due to missing data.
Bavaria's Prime Minister Markus Söder has urged the EMA for a swift approval of Sputnik V, emphasizing the need to avoid delays and ensure the vaccination process continues without interruption.

EMA Accepts Marketing Authorization Application for Alvotech's Golimumab Biosimilar, AVT05

The European Medicines Agency (EMA) has accepted the Marketing Authorization Application for AVT05, a biosimilar to Simponi (golimumab), developed by Alvotech.
AVT05 is intended for treating chronic inflammatory diseases like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, potentially expanding patient access to biologic medicines.

EMA Accepts Alvotech's Biosimilar Golimumab (AVT05) Application for Review

The European Medicines Agency (EMA) has accepted Alvotech's Marketing Authorization Application for AVT05, a biosimilar to Simponi® (golimumab).
AVT05 is intended for treating chronic inflammatory diseases, marking the first global filing for a golimumab biosimilar.

EMA Accepts Alvotech's Biosimilar Application for Simponi (Golimumab)

The European Medicines Agency (EMA) has accepted Alvotech's marketing authorization application for AVT05, a biosimilar to Simponi (golimumab).
AVT05 is intended for treating chronic inflammatory diseases, potentially expanding treatment options for patients across Europe.

Bavarian Nordic Initiates Phase II Trial to Expand Mpox Vaccine Label to Toddlers

Bavarian Nordic has commenced a Phase II trial to assess the safety and immunogenicity of its MVA-BN mpox/smallpox vaccine in children aged 2-11 years.
The trial, partially funded by CEPI, will compare the vaccine's performance in children to that in adults, with recruitment planned in the Democratic Republic of Congo and Uganda.

EMA Official Warns Against Unilateral Sputnik V Authorization, Cites Safety Concerns

An official from the European Medicines Agency (EMA) has cautioned against individual EU member states authorizing the Russian Sputnik V vaccine without prior EMA approval.
The EMA management board chair likened the unilateral authorization of Sputnik V to "Russian roulette," emphasizing the lack of sufficient data on the vaccine's safety.

Bavarian Nordic's Mpox Vaccine Shows Promise in Adolescents, Securing EMA Approval

Bavarian Nordic's mpox vaccine, MVA-BN (Imvanex), has received EMA approval for use in adolescents aged 12-17, potentially expanding access in Africa.
A NIH-sponsored clinical trial demonstrated that adolescents showed non-inferior immune responses and similar safety profiles to adults after two doses.

Reference News

[1]
Although not approved by the EMA, Bavaria is considering buying the Russian vaccine
telegrafi.com · Nov 27, 2024

Bavaria negotiated a preliminary contract for 2.5M doses of Sputnik V, pending EMA approval. If approved, Bavaria will r...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy